
|Articles|January 1, 2003
Glaucoma drugs may pose risk to ocular surface
Author(s)Julia Talsma
Orlando-Ophthalmologists should be aware of the risks to the ocular surface associated with long-term use of glaucoma medications, according to Robert J. Noecker, MD, MBA, who also spoke at the Cornea Health symposium during the American Academy of Ophthalmology annual meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
FDA approves NDA labeling supplement allowing re-administration of iDose TR
4
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain
5



























